BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol 2014;32:687-98. [PMID: 24449244 DOI: 10.1200/JCO.2013.49.7271] [Cited by in Crossref: 88] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng DT, Prasad M, Chekaluk Y, Benayed R, Sadowska J, Zehir A, Syed A, Wang YE, Somar J, Li Y, Yelskaya Z, Wong D, Robson ME, Offit K, Berger MF, Nafa K, Ladanyi M, Zhang L. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics 2017;10:33. [PMID: 28526081 DOI: 10.1186/s12920-017-0271-4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 11.4] [Reference Citation Analysis]
2 Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncol 2020;6:e196400. [PMID: 32027353 DOI: 10.1001/jamaoncol.2019.6400] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. J Natl Cancer Inst 2019;111:95-8. [PMID: 30239769 DOI: 10.1093/jnci/djy147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
4 Rotunno M, Barajas R, Clyne M, Hoover E, Simonds NI, Lam TK, Mechanic LE, Goldstein AM, Gillanders EM. A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer. Cancer Epidemiol Biomarkers Prev 2020;29:1519-34. [PMID: 32467344 DOI: 10.1158/1055-9965.EPI-19-1551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kamps-Hughes N, McUsic A, Kurihara L, Harkins TT, Pal P, Ray C, Ionescu-Zanetti C. ERASE-Seq: Leveraging replicate measurements to enhance ultralow frequency variant detection in NGS data. PLoS One 2018;13:e0195272. [PMID: 29630678 DOI: 10.1371/journal.pone.0195272] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. J Clin Oncol 2017;35:2232-9. [PMID: 28402748 DOI: 10.1200/JCO.2016.71.6480] [Cited by in Crossref: 138] [Cited by in F6Publishing: 63] [Article Influence: 27.6] [Reference Citation Analysis]
7 Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, Li X, Gao J, Schultz N, Cambria R, Galle J, Mukherjee S, Vijai J, Cadoo KA, Carlo MI, Walsh MF, Mandelker D, Ceyhan-Birsoy O, Shia J, Zehir A, Ladanyi M, Hyman DM, Zhang L, Offit K, Robson ME, Solit DB, Stadler ZK, Berger MF, Taylor BS. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet 2021;53:1577-85. [PMID: 34741162 DOI: 10.1038/s41588-021-00949-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sipeky C, Talala KM, Tammela TLJ, Taari K, Auvinen A, Schleutker J. Prostate cancer risk prediction using a polygenic risk score. Sci Rep 2020;10:17075. [PMID: 33051487 DOI: 10.1038/s41598-020-74172-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
9 Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S. Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2021.102337] [Reference Citation Analysis]
10 Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 2015;153:435-43. [PMID: 26296701 DOI: 10.1007/s10549-015-3545-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
11 Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, Hopper JL, Jenkins MA, Buchanan DD, Newcomb PA, Potter JD, Haile RW, Kucherlapati R, Syngal S;  Colon Cancer Family Registry. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol. 2015;1:214-221. [PMID: 26086041 DOI: 10.1001/jamaoncol.2015.0197] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
12 Lucci-Cordisco E, Amenta S, Panfili A, Del Valle J, Capellá G, Pineda M, Genuardi M. Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels? Eur J Med Genet 2022;65:104400. [PMID: 34813939 DOI: 10.1016/j.ejmg.2021.104400] [Reference Citation Analysis]
13 Marquardt JU, Andersen JB. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol. 2015;2:79-93. [PMID: 26257864 DOI: 10.2217/hep.14.24] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
14 McGee RB, Nichols KE. Introduction to cancer genetic susceptibility syndromes. Hematology Am Soc Hematol Educ Program 2016;2016:293-301. [PMID: 27913494 DOI: 10.1182/asheducation-2016.1.293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology 2015;149:604-13.e20. [PMID: 25980754 DOI: 10.1053/j.gastro.2015.05.006] [Cited by in Crossref: 147] [Cited by in F6Publishing: 119] [Article Influence: 21.0] [Reference Citation Analysis]
16 Birkeland AC, Uhlmann WR, Brenner JC, Shuman AG. Getting personal: Head and neck cancer management in the era of genomic medicine. Head Neck 2016;38 Suppl 1:E2250-8. [PMID: 25995036 DOI: 10.1002/hed.24132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
17 Alanazi M, Parine NR, Shaik JP, Al Naeem A, Aldhaian S. Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients. Saudi J Biol Sci 2020;27:2651-9. [PMID: 32994724 DOI: 10.1016/j.sjbs.2020.05.047] [Reference Citation Analysis]
18 Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, Ginsburg GS, Wu AC. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. J Pers Med 2018;8:E19. [PMID: 29772692 DOI: 10.3390/jpm8020019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
19 Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman DM, Zhang L, Klimstra D, Ladanyi M, Offit K, Berger M, Robson M. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol 2016;2:104-11. [PMID: 26556299 DOI: 10.1001/jamaoncol.2015.5208] [Cited by in Crossref: 166] [Cited by in F6Publishing: 159] [Article Influence: 27.7] [Reference Citation Analysis]
20 Li J, Dai Y, Wu L, Zhang M, Ouyang W, Huang J, Chen S. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia. Front Med 2021;15:347-71. [PMID: 33400146 DOI: 10.1007/s11684-020-0821-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Melas M, Subbiah S, Saadat S, Rajurkar S, McDonnell KJ. The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations. J Clin Med 2020;9:E2125. [PMID: 32640668 DOI: 10.3390/jcm9072125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, Wood S, Garraway L, Joffe S. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med 2016;18:1011-9. [PMID: 26866579 DOI: 10.1038/gim.2015.207] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 13.0] [Reference Citation Analysis]
23 Tsongalis GJ. The thrills and agonies of using next-generation sequencing for somatic mutation detection in cancer. Per Med 2014;11:369-71. [PMID: 29783481 DOI: 10.2217/pme.14.20] [Reference Citation Analysis]
24 Gray SW, Gollust SE, Carere DA, Chen CA, Cronin A, Kalia SS, Rana HQ, Ruffin MT 4th, Wang C, Roberts JS, Green RC. Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. J Clin Oncol 2017;35:636-44. [PMID: 27937091 DOI: 10.1200/JCO.2016.67.1503] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
25 Offit K. Decade in review--genomics: a decade of discovery in cancer genomics. Nat Rev Clin Oncol 2014;11:632-4. [PMID: 25286975 DOI: 10.1038/nrclinonc.2014.170] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
26 Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, Buchanan AH. Cancer Genetic Counseling and Testing in an Era of Rapid Change. J Genet Couns 2017;26:1244-53. [PMID: 28434142 DOI: 10.1007/s10897-017-0099-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
27 Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw 2017;15:219-28. [PMID: 28188191 DOI: 10.6004/jnccn.2017.0022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
28 Feliubadaló L, Tonda R, Gausachs M, Trotta JR, Castellanos E, López-Doriga A, Teulé À, Tornero E, Del Valle J, Gel B, Gut M, Pineda M, González S, Menéndez M, Navarro M, Capellá G, Gut I, Serra E, Brunet J, Beltran S, Lázaro C. Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Sci Rep 2017;7:37984. [PMID: 28050010 DOI: 10.1038/srep37984] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
29 Stoll J, Weissman SM, Hook N, Selkirk C, Johnson AK, Newlin A, Vogel Postula KJ. Evaluation of laboratory perspectives on hereditary cancer panels. Fam Cancer 2016;15:689-96. [PMID: 26869169 DOI: 10.1007/s10689-016-9880-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
30 Chan W, Lee M, Yeo ZX, Ying D, Grimaldi KA, Pickering C, Yang MMS, Sundaram SK, Tzang LCH. Development and validation of next generation sequencing based 35-gene hereditary cancer panel. Hered Cancer Clin Pract 2020;18:9. [PMID: 32368312 DOI: 10.1186/s13053-020-00141-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 L. Mendz G, O. Kaakoush N, A. Quinlivan J; 1 School of Medicine, Sydney, The University of Notre Dame Australia, 160 Oxford St, Darlinghurst, NSW 2010, Australia. . AIMS Microbiology 2016;2:55-68. [DOI: 10.3934/microbiol.2016.1.55] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). Cancer 2021. [PMID: 34890045 DOI: 10.1002/cncr.34063] [Reference Citation Analysis]
33 Loud JT, Bremer RC, Mai PL, Peters JA, Giri N, Stewart DR, Greene MH, Alter BP, Savage SA. Research participant interest in primary, secondary, and incidental genomic findings. Genet Med 2016;18:1218-25. [PMID: 27101135 DOI: 10.1038/gim.2016.36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
34 Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, Wubbenhorst B, Ravichandran V, Moore RM, Hu C, Guidugli L, Wenz B, Domchek SM, Robson ME, Szabo C, Neuhausen SL, Weitzel JN, Offit K, Couch FJ, Nathanson KL. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Am J Hum Genet 2016;98:801-17. [PMID: 27153395 DOI: 10.1016/j.ajhg.2016.02.024] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 15.8] [Reference Citation Analysis]
35 Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014;343:1466-70. [PMID: 24675953 DOI: 10.1126/science.1251827] [Cited by in Crossref: 214] [Cited by in F6Publishing: 189] [Article Influence: 26.8] [Reference Citation Analysis]
36 Samuel N, Villani A, Fernandez CV, Malkin D. Management of familial cancer: sequencing, surveillance and society. Nat Rev Clin Oncol 2014;11:723-31. [PMID: 25311347 DOI: 10.1038/nrclinonc.2014.169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
37 Baek IP, Jeong YB, Jung SH, Chung YJ. MAP: Mutation Arranger for Defining Phenotype-Related Single-Nucleotide Variant. Genomics Inform 2014;12:289-92. [PMID: 25705172 DOI: 10.5808/GI.2014.12.4.289] [Reference Citation Analysis]
38 Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, Bascuñana C, Borgida A, Hall A, Whelan T, Holter S, McPherson T, Cleary S, Petersen GM, Omeroglu A, Saloustros E, McPherson J, Stein LD, Foulkes WD, Majewski J, Gallinger S, Zogopoulos G. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Lett 2016;370:302-12. [PMID: 26546047 DOI: 10.1016/j.canlet.2015.10.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
39 Bijlsma RM, Bredenoord AL, Gadellaa-Hooijdonk CG, Lolkema MP, Sleijfer S, Voest EE, Ausems MG, Steeghs N. Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered. Eur J Hum Genet 2016;24:1496-500. [PMID: 27071717 DOI: 10.1038/ejhg.2016.27] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
40 Brnich SE, Rivera-Muñoz EA, Berg JS. Quantifying the potential of functional evidence to reclassify variants of uncertain significance in the categorical and Bayesian interpretation frameworks. Hum Mutat 2018;39:1531-41. [PMID: 30095857 DOI: 10.1002/humu.23609] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
41 Shin HC, Lee HB, Yoo TK, Lee ES, Kim RN, Park B, Yoon KA, Park C, Lee ES, Moon HG, Noh DY, Kong SY, Han W. Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test. Cancer Res Treat 2020;52:697-713. [PMID: 32019277 DOI: 10.4143/crt.2019.559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
42 Zhou JX, Yang X, Ning S, Wang L, Wang K, Zhang Y, Yuan F, Li F, Zhuo DD, Tang L, Zhuo D. Identification of KANSARL as the first cancer predisposition fusion gene specific to the population of European ancestry origin. Oncotarget 2017;8:50594-607. [PMID: 28881586 DOI: 10.18632/oncotarget.16385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
43 Offit K. The future of clinical cancer genomics. Semin Oncol 2016;43:615-22. [PMID: 27899195 DOI: 10.1053/j.seminoncol.2016.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
44 Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med 2015;17:630-8. [PMID: 25503501 DOI: 10.1038/gim.2014.176] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 10.8] [Reference Citation Analysis]
45 Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health 2017;20:40-6. [PMID: 28212967 DOI: 10.1016/j.jval.2016.09.2402] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
46 Kuhlen M, Borkhardt A. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr 2015;174:987-97. [PMID: 25982339 DOI: 10.1007/s00431-015-2565-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
47 Bradbury AR, Patrick-Miller L, Long J, Powers J, Stopfer J, Forman A, Rybak C, Mattie K, Brandt A, Chambers R, Chung WK, Churpek J, Daly MB, Digiovanni L, Farengo-Clark D, Fetzer D, Ganschow P, Grana G, Gulden C, Hall M, Kohler L, Maxwell K, Merrill S, Montgomery S, Mueller R, Nielsen S, Olopade O, Rainey K, Seelaus C, Nathanson KL, Domchek SM. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med 2015;17:485-92. [PMID: 25297947 DOI: 10.1038/gim.2014.134] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
48 Hamilton JG, Robson ME. Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. Hastings Cent Rep 2019;49 Suppl 1:S44-52. [PMID: 31268573 DOI: 10.1002/hast.1016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
49 Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME; Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), in collaboration with the Breast Cancer Surveillance Consortium (BCSC), and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol 2022. [PMID: 35175286 DOI: 10.1001/jamaoncol.2021.6204] [Reference Citation Analysis]
50 Ng ZX, Ong MS, Jegadeesan T, Deng S, Yap CT. Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment. Healthcare (Basel) 2017;5:E26. [PMID: 28538673 DOI: 10.3390/healthcare5020026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
51 Young EL, Feng BJ, Stark AW, Damiola F, Durand G, Forey N, Francy TC, Gammon A, Kohlmann WK, Kaphingst KA, McKay-Chopin S, Nguyen-Dumont T, Oliver J, Paquette AM, Pertesi M, Robinot N, Rosenthal JS, Vallee M, Voegele C, Hopper JL, Southey MC, Andrulis IL, John EM, Hashibe M, Gertz J, Le Calvez-Kelm F, Lesueur F, Goldgar DE, Tavtigian SV; Breast Cancer Family Registry. Multigene testing of moderate-risk genes: be mindful of the missense. J Med Genet 2016;53:366-76. [PMID: 26787654 DOI: 10.1136/jmedgenet-2015-103398] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
52 Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 2017;123:3925-32. [PMID: 28657667 DOI: 10.1002/cncr.30817] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
53 Castellanos E, Gel B, Rosas I, Tornero E, Santín S, Pluvinet R, Velasco J, Sumoy L, Del Valle J, Perucho M, Blanco I, Navarro M, Brunet J, Pineda M, Feliubadaló L, Capellá G, Lázaro C, Serra E. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Sci Rep 2017;7:39348. [PMID: 28051113 DOI: 10.1038/srep39348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
54 Terraf P, Pareja F, Brown D, Ceyhan-birsoy O, Misyura M, Rana S, O’reilly E, Carlo M, Aghajanian C, Liu Y, Derakhshan F, Jayakumaran G, Weigelt B, Walsh M, Stadler Z, Offit K, Ladanyi M, Robson M, Zehir A, Reis-filho J, Mandelker D. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.01.006] [Reference Citation Analysis]
55 Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X, Wan L, Zhang Z, Zhang C, Qin X, Xiao M, Ye D, Liu Y, Han Z, Wang S, Mao L, Wei W, Chen W. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J 2017;36:1243-60. [PMID: 28320739 DOI: 10.15252/embj.201694058] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
56 Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 2016;18:530-2. [PMID: 27034017 DOI: 10.4103/1008-682X.175785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
57 Pelosi G, Papotti M, Rindi G, Scarpa A. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 2014;25:151-64. [PMID: 24771462 DOI: 10.1007/s12022-014-9320-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
58 Ryu JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo J, Lee ES, Kang HS, Lee S, Lee DO, Lim MC, Kong SY. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Cancer Sci 2020;111:3912-25. [PMID: 32761968 DOI: 10.1111/cas.14600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]